PETALING JAYA: Earnings contribution for the potential supply of Sinopharm Covid-19 vaccine to the government by Duopharma Biotech Bhd is expected to be marginal. The company on Friday received a conditional registration approval for the vaccine and is likely to sign an agreement by month-end with more details to be announced then. Duopharma is also awaiting approval to supply Russia’s Sputnik V vaccine( pic below) to the Malaysian government....
But for now, even the World Health Organisation
综合
星报-商业
2021-07-20 00:00:00.0